Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
Axsome Therapeutics has announced the approval of AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease. The company discussed the implications of this approval during a recent conference call. AUVELITY's new indication marks a significant development in addressing behavioral symptoms in Alzheimer's patients.
- ▪Axsome Therapeutics received approval for AUVELITY to treat agitation associated with dementia due to Alzheimer's disease.
- ▪The approval was discussed in a May 1, 2026 conference call involving company executives and financial analysts.
- ▪AUVELITY is now indicated for a new psychiatric symptom in Alzheimer's patients, expanding its therapeutic use.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897438-axsome-therapeutics-inc-axsm-discusses-approval-of-auvelity-for-agitation-associated-with"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
